HBVAXPRO 10 micrograms/mlSuspension for injection in pre-filled syringeHepatitis B vaccine (rDNA)

This vaccine is indicated for active immunisation against hepatitis B virus infection caused by all known subtypes in adults and adolescents (16 years of age and older) considered at risk of exposure to hepatitis B virus.

It can be expected that hepatitis D will also be prevented by immunisation with HBVAXPRO as hepatitis D does not occur in the absence of hepatitis B infection.

The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E and other pathogens known to infect the liver.

Do not use HBVAXPRO 10 micrograms/ml:

• if you are allergic (hypersensitive) to hepatitis B surface antigen or to any of the other ingredients of HBVAXPRO (see section 6.)
• if you have a severe febrile illness

Take special care withHBVAXPRO 10 micrograms/ml:

Pregnancy and Breast-feeding:

Caution should be exercised when prescribing to pregnant women.
Breast-feeding is not a contraindication.
Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines:

Some of the rare effects may affect the ability to drive or operate machinery.

Using other vaccines:

This vaccine can be administered simultaneously with hepatitis B immunoglobulin, at a separate injection site.
This vaccine can be used to complete a primary immunisation course or as a booster dose in subjects who have previously received another hepatitis B vaccine.
This vaccine can be administered concomitantly with other vaccines, using separate sites and syringes.

Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Posology:

The recommended dose for each injection (1 ml) is 10 micrograms for adults and adolescents (16 years of age and older).

A course of vaccination should include at least three injections.

Two immunisation schedules can be recommended:

• two injections with an interval of one month followed by a third injection 6 months after the first administration (0,1,6 months)
• three injections with an interval of one month and a fourth dose 1 year later, if a rapid immunity is requested (0,1,2,12 months).

In case of a recent exposure to the hepatitis B virus, a first dose of HBVAXPRO together with the appropriate dose of immunoglobulin can be given.

Some local vaccination schedules currently include recommendations for a booster dose. Your doctor or pharmacist will inform you if a booster dose should be given.

Method of administration:

It should be well shaken until a slightly opaque white suspension is obtained.
The needle is attached by twisting in clockwise direction, until the needle fits securely on the syringe. The doctor will give the vaccine as an injection into muscle. The upper arm muscle is the preferred site for injection in adults and adolescents.

This vaccine should never be given into a vein.

Exceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopoenia (diminution of blood platelets) or to persons at risk of haemorrhage.

If you forget one dose of HBVAXPRO 10 micrograms/ml:

If you miss a scheduled injection, your doctor will decide when to give the missed dose.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Like all medicines, HBVAXPRO can cause side effects, although not everybody gets them.

As with other hepatitis B vaccines, in many instances, the causal relationship of side effects to the vaccine has not been established.

HBVAXPRO is generally well tolerated.
The most common side effects seen are injection-site reactions: soreness, redness and hardening. Other side effects are reported very rarely: low platelet count, lymph node disease, allergic reactions, nervous system disorders such as pins and needles, facial paralysis, nerve inflammations including Guillain-Barre Syndrome, inflammation of the nerve of the eye that leads to impaired vision, brain inflammation, exacerbation of multiple sclerosis, multiple sclerosis, convulsions, headache, dizziness and fainting, low blood pressure, blood vessel inflammation, asthma-like symptoms, vomiting, nausea, diarrhoea, abdominal pain, skin reactions such as eczema, rash, hair loss, itching, hives and skin blistering, joint pain, arthritis, muscle pain, pain in extremity, fatigue, fever, vague illness, flu-like symptoms and elevations of liver enzymes.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist .

Keep out of the reach and sight of children.

Do not use HBVAXPRO after the expiry date which is stated on the label.

Store in a refrigerator (2 °C ? 8 °C)
Do not freeze

What HBVAXPRO 10 micrograms/ml contains

The active substance is, for one dose of 1 ml:
Hepatitis B virus surface antigen, recombinant (HBsAg) *...................10.00 micrograms Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.50 milligram Al +)

* produced from recombinant strain of the yeast Saccharomyces cerevisiae (strain 2150-2-3)

The other ingredients are sodium chloride, borax and water for injections.

What HBVAXPRO 10 micrograms/ml looks like and contents of the pack

Each dose contains 1 ml of suspension for injection in a syringe.
Pack sizes of 1, 10 and 20 pre-filled syringes with 2 separate needles.
Pack sizes of 1 and 10 pre-filled syringes without needle, or with 1 separate needle.
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder: Sanofi Pasteur MSD SNC, 8 rue Jonas Salk, F-69007 Lyon, France

Manufacturer Responsible for Batch Release: Merck Sharp and Dohme, B.V., Waarderweg, 39, 2031 BN Haarlem, The Netherlands

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.

België/Belgique/Belgien: Sanofi Pasteur MSD, Tél/Tel: +32.2.726.95.84
--------: ---- ---- - ---- -------- ----, ---. + 359 2 8193740
-eská republika: Merck Sharp & Dohme, IDEA, Inc., org. sl., Tel.: +420.233.010.111 Danmark: Sanofi Pasteur MSD, Tlf: +45 23 32 69 29
Deutschland: Sanofi Pasteur MSD GmbH, Tel: +49.6224.5940
Eesti: Merck Sharp & Dohme OÜ, Tel: +372.613.9750
???-??: ?????? ?.?., ???: +30.210.8009111
España: Sanofi Pasteur MSD S.A., Tel: +34.91.371.78.00
France: Sanofi Pasteur MSD SNC, Tél: +33.4.37.28.40.00
Ireland: Sanofi Pasteur MSD Ltd, Tel: +3531.468.5600
Ísland: Sanofi Pasteur MSD, Tel: +32.2.726.95.84
Italia: Sanofi Pasteur MSD Spa, Tel: +39.06.664.092.11
K-????: Merck Sharp & Dohme (Middle East) Limited., ???: +357 22866700
Latvija: SIA Merck Sharp & Dohme Latvija, Tel: +371.67364.224
Lietuva: UAB Merck Sharp & Dohme, Tel.: +370.5.2780.247
Luxembourg/Luxemburg: Sanofi Pasteur MSD, Tél: +32.2.726.95.84
Magyarország: MSD Magyarország Kft, Tel.: + 36.1.888.5300
Malta: Merck Sharp & Dohme (Middle East) Limited, Tel: +357 22866700
Nederland: Sanofi Pasteur MSD, Tel: +31.23.567.96.00
Norge: Sanofi Pasteur MSD, Tlf: +47.67.50.50.20
Österreich: Sanofi Pasteur MSD GmbH, Tel: +43.1.866.70.22.202
Polska: MSD Polska Sp. z o.o., Tel.: +48.22.549.51.00
Portugal: Sanofi Pasteur MSD, SA, Tel: +351 21 470 45 50
România: Merck Sharp & Dohme Romania S.R.L., Tel: + 4021 529 29 00
Slovenija: Merck Sharp & Dohme, inovativna zdravila d.o.o., Tel: +386.1.520.4201
Slovenská republika: Merck Sharp & Dohme IDEA, Inc., Tel: +421.2.58282010
Suomi/Finland: Sanofi Pasteur MSD, Puh/Tel: +358.9.565.88.30
Sverige: Sanofi Pasteur MSD, Tel: +46.8.564.888.60
United Kingdom: Sanofi Pasteur MSD Ltd, Tel: +44 1 628 785 291

This leaflet was last approved in ????..